Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells

被引:58
|
作者
Hasei, Joe [1 ]
Sasaki, Tsuyoshi [1 ]
Tazawa, Hiroshi [2 ,4 ]
Osaki, Shuhei [1 ]
Yamakawa, Yasuaki [1 ]
Kunisada, Toshiyuki [1 ,3 ]
Yoshida, Aki [1 ]
Hashimoto, Yuuri [2 ]
Onishi, Teppei [2 ]
Uno, Futoshi [2 ]
Kagawa, Shunsuke [2 ]
Urata, Yasuo [5 ]
Ozaki, Toshifumi [1 ]
Fujiwara, Toshiyoshi [2 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthopaed Surg, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg Gastroenterol, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med Mat Musculoskeletal Reconstruct, Okayama 7008558, Japan
[4] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[5] Oncolys BioPharma Inc, Tokyo, Japan
关键词
GENE-THERAPY; TELOMERASE ACTIVITY; PROGNOSTIC-FACTORS; DOWN-REGULATION; EXPRESSING P53; CANCER-CELLS; LUNG-CANCER; SOFT-TISSUE; APOPTOSIS; GROWTH;
D O I
10.1158/1535-7163.MCT-12-0869
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells. Mol Cancer Ther; 12(3); 314-25. (C)2012 AACR.
引用
收藏
页码:314 / 325
页数:12
相关论文
共 50 条
  • [2] Oncolytic adenoviral therapy with p53 transactivation induces profound immunogenic cell death in osteosarcoma
    Demiya, Koji
    Tazawa, Hiroshi
    Mochizuki, Yusuke
    Komatsubara, Tadadshi
    Sugiu, Kazuhisa
    Hasei, Joe
    Kunisada, Toshiyuki
    Urata, Yasuo
    Ozaki, Toshifumi
    Fujiwara, Toshiyoshi
    CANCER SCIENCE, 2018, 109 : 1413 - 1413
  • [3] Oncolytic adenovirus-mediated p53 transactivation induces profound immunogenic cell death in pancreatic cancer
    Araki, Hiroyuki
    Tazawa, Hiroshi
    Fushimi, Takuro
    Kanaya, Nobuhiko
    Kikuchi, Satoru
    Kuroda, Shinji
    Yoshida, Ryuichi
    Kishimoto, Hiroyuki
    Nishizaki, Masahiko
    Urata, Yasuo
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    CANCER SCIENCE, 2018, 109 : 754 - 754
  • [4] p53-mediated apoptotic signaling overcomes the resistance to oncolytic adenovirus in human osteosarcoma cells
    Hasel, Joe
    Sasaki, Tsuyoshi
    Tazawa, Hiroshi
    Hashimoto, Yuuri
    Kunisada, Toshiyuki
    Urata, Yasuo
    Ozaki, Toshifumi
    Fujiwara, Toshiyoshi
    CANCER RESEARCH, 2012, 72
  • [5] The p53 family and programmed cell death
    E C Pietsch
    S M Sykes
    S B McMahon
    M E Murphy
    Oncogene, 2008, 27 : 6507 - 6521
  • [6] The p53 family and programmed cell death
    Pietsch, E. C.
    Sykes, S. M.
    McMahon, S. B.
    Murphy, M. E.
    ONCOGENE, 2008, 27 (50) : 6507 - 6521
  • [7] Regulation of programmed cell death by the p53 pathway
    Kuribayashi, Kageaki
    El-Deiry, Wafik S.
    PROGRAMMED CELL DEATH IN CANCER PROGRESSION AND THERAPY, 2008, 615 : 201 - 221
  • [8] The role of p53 gene in programmed cell death
    Chumakov, PM
    IZVESTIYA AKADEMII NAUK SERIYA BIOLOGICHESKAYA, 1998, (02): : 151 - 156
  • [9] Apoptotic and autophagic cell death induced in cervical cancer cells by a dual specific oncolytic adenovirus
    Li, Shanzhi
    Li, Zhuoxin
    Chen, Shuang
    Zhu, Yilong
    Li, Yiquan
    Yin, Xunzhe
    Li, Xiao
    Zhu, Guangze
    ANTI-CANCER DRUGS, 2023, 34 (03) : 361 - 372
  • [10] DRAM links autophagy to p53 and programmed cell death
    Crighton, Diane
    Wilkinson, Simon
    Ryan, Kevin M.
    AUTOPHAGY, 2007, 3 (01) : 72 - 74